Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Hong‐Hong Yan's publication output changed over time?
ScholarIQpublication output · 2011–2022
Output grew100% over the shown period — from 1 works in 2011 to 2 in 2022.
1
1
2
1
1
1
2
2
20112012201620172018201920202022
What are the most-cited papers on Hong‐Hong Yan?
ScholarIQmost cited works
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang, Jian Su, Zhi Xie, Si‐Yang Maggie Liu, Hai‐Yan Tu, Hua‐Jun Chen, Yue‐Li Sun, Qing Zhou, Jin‐Ji Yang, Xue‐Ning Yang, Jiaxin Lin, Hong‐Hong Yan, Hao-Ran Zhai, Li‐Xu Yan, Ri-Qiang Liao, Si-Pei Wu, Yi‐Long Wu
Clinical Cancer Research. 2016999 Citations
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen‐Zhao Zhong, Qun Wang, Weimin Mao, Lin Xu, Lin Wu, Yi Shen, Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Fei Ke, Xiaofei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Ke‐Neng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Hong‐Hong Yan, Xue‐Ning Yang, Qing Zhou, Yi‐Long Wu, Yi‐Long Wu, Qun Wang, Weimin Mao, Lin Wu, Yi Shen, Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Fei Ke, Xiaofei Li, Jian Li, Cheng Zhi Huang, Zhidong Liu, Shun Xu, Ke‐Neng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Siyu Wang, Jian Hu, Wei Liu, Wěi Li, Jianhua Shi
The Lancet Oncology. 2017530 Citations
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
Y.S. Li, Bo Jiang, Jin‐Ji Yang, X.C. Zhang, Zhou Zhang, J.Y. Ye, Wen‐Zhao Zhong, Hai‐Yan Tu, H.J. Chen, Z. Wang, Chong‐Rui Xu, B.C. Wang, Hao Du, Shaokun Chuai, Han Han‐Zhang, Jian Su, Qing Zhou, Xue‐Ning Yang, Wanting Guo, Hong‐Hong Yan, Y.H. Liu, Li‐Xu Yan, Biao Huang, Mei-Mei Zheng, Yi‐Long Wu
Annals of Oncology. 2018331 CitationsOPEN ACCESS
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Yang-Si Li, Ben‐Yuan Jiang, Jin‐Ji Yang, Hai‐Yan Tu, Qing Zhou, Wei‐Bang Guo, Hong‐Hong Yan, Yi‐Long Wu
Journal of Thoracic Oncology. 2016326 CitationsOPEN ACCESS
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Wen-Zhao Zhong, Qun Wang, Weimin Mao, Lin Xu, Lin Wu, Yucheng Wei, Yong-Yu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Shengxiang Ren, Xiaofei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Ke‐Neng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Jin‐Ji Yang, Hong‐Hong Yan, Xue‐Ning Yang, Si‐Yang Liu, Qing Zhou, Yi‐Long Wu
Journal of Clinical Oncology. 2020281 CitationsOPEN ACCESS
Related on ScholarIQ
Guy's and St Thomas' NHS Foundation Trust
Institution
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Paper
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Paper
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
Paper
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Paper
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Paper